e11vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 11-K
ANNUAL REPORT
Pursuant to Section 15(d) of the
Securities Exchange Act of 1934
|
|
|
þ |
|
ANNUAL REPORT PURSUANT TO SECTION 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934 |
FOR THE FISCAL YEAR ENDED DECEMBER 31, 2007
or
|
|
|
o |
|
TRANSITION REPORT PURSUANT TO SECTION 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934 |
Commission File Number 001-13305
A. Full title of the plan and address of the plan, if different from that of the issuer named below:
WATSON PHARMACEUTICALS, INC.
401(K) PLAN
B. Name of issuer of the securities held pursuant to the plan and the address of its principal executive office:
WATSON PHARMACEUTICALS, INC.
311 Bonnie Circle
Corona, CA 92880
Watson Pharmaceuticals, Inc.
401(k) Plan
Index to Financial Statements
and Supplemental Schedule
|
|
|
|
|
|
|
Page |
|
|
|
1 |
|
|
|
|
|
|
Financial Statements: |
|
|
|
|
|
|
|
|
|
|
|
|
2 |
|
|
|
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
4 |
|
|
|
|
|
|
Supplemental Schedule*: |
|
|
|
|
|
|
|
|
|
|
|
|
13 |
|
|
|
|
|
|
|
|
|
14 |
|
|
|
|
|
|
|
|
|
15 |
|
|
|
|
* |
|
All other schedules required by the Department of Labor Rules and Regulations for Reporting and
Disclosure under the Employee Retirement Income Security Act of 1974 have been omitted because
they are not applicable. |
Report of Independent Registered Public Accounting Firm
To the Participants and the Employee Benefit Plans Committee
for the Watson Pharmaceuticals, Inc. 401(k) Plan:
We have audited the accompanying statements of net assets available for benefits of the
Watson Pharmaceutical, Inc., Employees 401(k) Plan (the Plan) as of December 31, 2007 and
2006, and the related statement of changes in net assets available for benefits for each of
the years in the two year period ended December 31, 2007. These financial statements are the
responsibility of the Plans management. Our responsibility is to express an opinion on
these financial statements based on our audit.
We conducted our audits in accordance with the standards of the Public Company Accounting
Oversight Board (United States). Those standards require that we plan and perform the audits
to obtain reasonable assurance about whether the financial statements are free of material
misstatement. Our audit included consideration of internal control over financial reporting
as a basis for designing audit procedures that are appropriate in the circumstances, but not
for the purpose of expressing an opinion on the effectiveness of the Companys internal
control over financial reporting. Accordingly, we express no such opinion. An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material
respects, the net assets available for benefits of the Plan as of December 31, 2007 and 2006,
and the changes in net assets available for benefits for each of the years in the two year
period ended December 31, 2007 in conformity with accounting principles generally accepted in
the United States of America.
Our audits were conducted for the purpose of forming an opinion on the basic financial
statements taken as a whole. The supplemental schedule of assets (held at end of year) at
December 31, 2007 is presented for the purpose of additional analysis and is not a required
part of the basic financial statements, but is supplementary information required by the
Department of Labors Rules and Regulations for Reporting and Disclosure under the Employee
Retirement Income Security Act of 1974. This supplemental schedule is the responsibility of
the Plans management. The supplemental schedule has been subjected to the auditing
procedures applied in the audits of the basic financial statements and, in our opinion, is
fairly stated in all material respects in relation to the basic financial statements taken as
a whole.
As discussed in Note 2, the Plan adopted Financial Accounting Standards Board Staff Position
AAG INV-1 and SOP 94-4-1, Reporting of Fully Benefit-Responsive Investment Contracts Held by
Certain Investment Companies Subject to the AICPA Investment Company Guide and Defined
Contribution Health and Welfare and Pension Plans, in fiscal 2006.
Moss Adams LLP
Orange County, CA
June 30, 2008
1
Watson Pharmaceuticals, Inc.
401(k) Plan
Statements of Net Assets Available for Benefits
December 31, 2007 and 2006
|
|
|
|
|
|
|
|
|
|
|
2007 |
|
|
2006 |
|
Assets |
|
|
|
|
|
|
|
|
Investments
|
|
|
|
|
|
|
|
|
Investments, at fair value |
|
$ |
209,286,512 |
|
|
$ |
182,636,166 |
|
Loans to participants |
|
|
5,790,771 |
|
|
|
5,485,021 |
|
|
|
|
|
|
|
|
Total investments |
|
|
215,077,283 |
|
|
|
188,121,187 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contributions receivable |
|
|
|
|
|
|
|
|
Company |
|
|
808,355 |
|
|
|
722,546 |
|
Participant |
|
|
568,886 |
|
|
|
472,392 |
|
|
|
|
|
|
|
|
Total contributions receivable |
|
|
1,377,241 |
|
|
|
1,194,938 |
|
|
|
|
|
|
|
|
Net assets available for benefits at fair value |
|
|
216,454,524 |
|
|
|
189,316,125 |
|
|
|
|
|
|
|
|
|
|
Adjustment from fair value to contract value for fully
benefit-responsive investment contracts |
|
|
(274,427 |
) |
|
|
(316,798 |
) |
|
|
|
|
|
|
|
Net assets available for benefits |
|
$ |
216,180,097 |
|
|
$ |
188,999,327 |
|
|
|
|
|
|
|
|
See accompanying Notes to Financial Statements.
2
Watson Pharmaceuticals, Inc.
401(k) Plan
Statements of Changes in Net Assets Available for Benefits
Years Ended December 31, 2007 and 2006
|
|
|
|
|
|
|
|
|
|
|
2007 |
|
|
2006 |
|
Additions to net assets |
|
|
|
|
|
|
|
|
Investment income |
|
|
|
|
|
|
|
|
Interest and dividend income |
|
$ |
11,763,573 |
|
|
$ |
7,464,394 |
|
Net appreciation in fair value of investments |
|
|
2,529,004 |
|
|
|
6,483,418 |
|
|
|
|
|
|
|
|
Total investment income |
|
|
14,292,577 |
|
|
|
13,947,812 |
|
|
|
|
|
|
|
|
Contributions |
|
|
|
|
|
|
|
|
Company |
|
|
8,647,901 |
|
|
|
6,823,466 |
|
Participant |
|
|
21,408,145 |
|
|
|
17,332,144 |
|
Rollover |
|
|
7,007,951 |
|
|
|
23,192,639 |
|
|
|
|
|
|
|
|
Total contributions |
|
|
37,063,997 |
|
|
|
47,348,249 |
|
|
|
|
|
|
|
|
Total additions |
|
|
51,356,574 |
|
|
|
61,296,061 |
|
|
|
|
|
|
|
|
Deductions from net assets |
|
|
|
|
|
|
|
|
Benefits paid to participants |
|
|
(23,966,533 |
) |
|
|
(10,766,342 |
) |
Deemed distributions |
|
|
(4,316 |
) |
|
|
(37,129 |
) |
Refund of excess contribution |
|
|
(3,151 |
) |
|
|
|
|
Administrative expenses |
|
|
(201,804 |
) |
|
|
(88,302 |
) |
|
|
|
|
|
|
|
Total deductions |
|
|
(24,175,804 |
) |
|
|
(10,891,773 |
) |
|
|
|
|
|
|
|
Net increase |
|
|
27,180,770 |
|
|
|
50,404,288 |
|
|
|
|
|
|
|
|
|
|
Net assets available for benefits |
|
|
|
|
|
|
|
|
Beginning of year |
|
|
188,999,327 |
|
|
|
138,595,039 |
|
|
|
|
|
|
|
|
End of year |
|
$ |
216,180,097 |
|
|
$ |
188,999,327 |
|
|
|
|
|
|
|
|
See accompanying Notes to Financial Statements.
3
Watson Pharmaceuticals, Inc.
401(k) Plan
Notes to Financial Statements
December 31, 2007 and 2006
1. Description of Plan
The following description of the Watson Pharmaceuticals, Inc. 401(k) Plan (the Plan)
provides only general information. Participants should refer to the Plan agreement for a
more complete description of the Plans provisions.
General
The Plan was adopted by Watson Pharmaceuticals, Inc., and certain subsidiaries (collectively,
the Company) on January 1, 1988. The Plan is a defined contribution plan covering
substantially all United States based employees of the Company who have met certain
eligibility requirements. The Plan is subject to the provisions of the Employee Retirement
Income Security Act of 1974 (ERISA) and is administered by the Employee Benefit Plans
Committee of Watson Pharmaceuticals, Inc. (the Plans Committee).
The Plan is intended to be a qualified defined contribution plan, which satisfies the
requirements of Section 401(k) of the Internal Revenue Code, as amended (the IRC). Under
the IRC, participants are not liable for federal income taxes on employee contributions,
Company contributions or Plan earnings thereon until such time as they are partially or
completely withdrawn from the Plan.
Effective April 1, 2005, the Plan trustee and custodian is Vanguard Fiduciary Trust Company
and its record-keeper is The Vanguard Group, Inc. Effective January 1, 2006, the plan name
was changed to Watson Pharmaceuticals, Inc., 401(k) Plan.
The Company acquired Andrx Corporation on November 3, 2006. Andrx employees were eligible to
participate in the Plan immediately after the acquisition date. These participants were able
to rollover balances from the Andrx Corporation 401(k) Plan into the Plan. The Plan was
amended to permit the direct rollover of participants notes related to plan loans under the
Andrx Corporation 401(k) Plan.
Vesting
Participant contributions and related earnings are fully vested immediately. Effective
January 1, 2006, participants are fully vested in Company matching contributions at a rate
per year of 33%, 33% and 34%. Benefits attributable to each participant will become fully
vested in all accounts in the event of death, disability, normal retirement at age 65, or the
complete or partial termination of
the Plan. Refer to Note 6. Subsequent Events for information on changes to Plan vesting
effective January 1, 2008.
Contributions
Effective January 1, 2006, the Company made changes that allow participants to contribute up
to 50% of his or her eligible pay up to the IRS limit. In addition, the Company has
eliminated the requirement that eligible employees must be age 21 before they can begin
participating in the Plan. Participants may also make rollover contributions from all other
qualified plans.
The Company contributes 50% of the first 8% of total eligible compensation that a participant
contributes to the Plan. In addition to these matching contributions, the Company may elect
to make discretionary profit sharing contributions. The Company did not make any
discretionary profit sharing contributions during the years ended December 31, 2007 and 2006.
Refer to Note 6.
4
Watson Pharmaceuticals, Inc.
401(k) Plan
Notes to Financial Statements
December 31, 2007 and 2006
Subsequent Events for information on changes to Plan Company matching
contributions effective January 1, 2008.
The Plan failed the actual deferral percentage (ADP) test for plan year 2006 but passed the
actual contribution percentage (ACP) test. The ADP test was corrected by the Company making
a qualified non-elective contribution (QNEC) to statistically identified non-highly
compensated plan participants. The QNEC was funded on April 17, 2007 in the amount of
$166,500. Further, from April 30, 2007 to December 31, 2007, the contribution limit for
highly compensated employees was capped at 6%.
Participant Accounts
Each participants account is credited with (a) participant contributions, (b) Company
matching contributions, (c) discretionary profit-sharing contributions, if any, and (d) an
allocation of investment earnings, losses, or expenses thereon to the participants account
in the same proportion as the participants beginning account balance invested in the fund
(as defined in the Plan) in relation to the total fund balance. Loan interest is credited to
the investment funds of the participant making the payment. The benefit to which a
participant is entitled is the benefit that can be provided from the participants vested
account. Participants direct the investment of their accounts. Changes to these investment
elections are allowed at any time.
Investment Options
The investment fund options for the years ended December 31, 2007 and 2006 consist of various
registered investment company mutual funds and a Company stock fund, which are generally
described below:
T. Rowe Price Mid-Cap Growth Fund
The fund normally invests at least 80% of its assets in a diversified portfolio of common
stocks of mid-capitalization companies that offer the potential for above average earnings
growth.
Vanguard Retirement Savings Trust
The trust normally invests in high quality fixed income securities with financial backing
from insurance companies and banks that enable it to maintain a constant $1 per share net
asset value.
PIMCO Total Return Fund
The fund normally invests in bonds maintaining an average duration ranging between three to
six years.
Vanguard Target Retirement 2050 Fund
The fund normally invests in other Vanguard mutual funds according to an asset allocation
strategy designed for investors planning to retire in or within a few years of 2050.
Vanguard Target Retirement 2045 Fund
The fund normally invests in other Vanguard mutual funds according to an asset allocation
strategy designed for investors planning to retire in or within a few years of 2045.
Vanguard Target Retirement 2040 Fund
The fund normally invests in other Vanguard mutual funds according to an asset allocation
strategy designed for investors planning to retire in or within a few years of 2040.
5
Watson Pharmaceuticals, Inc.
401(k) Plan
Notes to Financial Statements
December 31, 2007 and 2006
Vanguard Target Retirement 2035 Fund
The fund normally invests in other Vanguard mutual funds according to an asset allocation
strategy designed for investors planning to retire in or within a few years of 2035.
Vanguard Target Retirement 2030 Fund
The fund normally invests in other Vanguard mutual funds according to an asset allocation
strategy designed for investors planning to retire in or within a few years of 2030.
Vanguard Target Retirement 2025 Fund
The fund normally invests in other Vanguard mutual funds according to an asset allocation
strategy designed for investors planning to retire in or within a few years of 2025.
Vanguard Target Retirement 2020 Fund
The fund normally invests in other Vanguard mutual funds according to an asset allocation
strategy designed for investors planning to retire in or within a few years of 2020.
Vanguard Target Retirement 2015 Fund
The fund normally invests in other Vanguard mutual funds according to an asset allocation
strategy designed for investors planning to retire in or within a few years of 2015.
Vanguard Target Retirement 2010 Fund
The fund normally invests in other Vanguard mutual funds according to an asset allocation
strategy designed for investors planning to retire in or within a few years of 2010.
Vanguard Target Retirement 2005 Fund
The fund normally invests in other Vanguard mutual funds according to an asset allocation
strategy designed for investors planning to retire in or within a few years of 2005.
Vanguard Target Retirement Income Fund
The fund normally invests in other Vanguard mutual funds according to an asset allocation
strategy designed for investors currently in retirement.
Vanguard Windsor II Fund
The fund normally invests in a diversified group of out-of-favor stocks of large
capitalization companies. It is managed by five advisors, each of whom runs its portion of
the fund independently.
Vanguard 500 Index Fund
The fund employs a passive management or indexing-investment approach designed to track the
performance of the Standard & Poors 500 Index, a widely recognized benchmark of U.S. stock
market performance that is dominated by the stocks of large U.S. companies.
Vanguard Morgan Growth Fund
The fund invests primarily in stocks of large and medium-sized companies that have strong
records of growth in sales and earnings or that have performed well during certain market
cycles. The fund also invests in stocks of smaller companies that offer good prospects for
growth.
6
Watson Pharmaceuticals, Inc.
401(k) Plan
Notes to Financial Statements
December 31, 2007 and 2006
Artisan Mid Cap Value Fund
The fund normally invests in a diversified portfolio of stocks of medium-sized U.S. companies
that Artisan considers to be undervalued, in solid financial condition, and to provide a
controlled level of risk.
Vanguard Mid-Cap Index Fund
The fund employs a passive management- or indexing-investment approach designed to track
the performance of the MSCI US Mid Cap 450 Index, a broadly diversified index of stocks of
medium-size U.S. companies.
American Aadvantage Small Cap Value Fund (previously known as)/ American Beacon Small Cap
Value Fund
The fund normally invests at least 80% of its assets in equity securities of small market
capitalization U.S. companies.
Vanguard Explorer Fund
The fund normally invests in the stocks of smaller companies. These companies are considered
by the advisors to have above average prospects for growth, but often provide little or no
dividend income.
T. Rowe Price Small-Cap Stock (Advisor Class) Fund
The fund normally invests at least 80% of total assets in the stocks of small companies
those with market capitalizations that fall within the range of companies in the Russell 2000
Index, a widely used benchmark for small cap stock performance.
American Funds EuroPacific Growth Fund
The fund normally invests at least 80% of total assets in securities of issuers located in
Europe and the Pacific Basin.
Company Stock Fund
The fund invests in shares of Watson Pharmaceuticals, Inc. common stock (Company common
stock).
Participant Loans
Participants may borrow a minimum of $1,000 and a maximum equal to the lesser of $50,000 or
50% of the participants vested account balance. Each loan is collateralized by the
participants vested account balance and bears interest commensurate with local prevailing
rates as determined by the Plans Committee. Repayment of principal and interest is provided
by uniform payroll deductions over a period of up to five years for all loans unless loan
proceeds were used to purchase a primary residence. The period for repayment of loans used
for purchase of a primary residence have a maximum repayment term of 15 years.
Payment of Benefits
Upon termination of service due to separation from the Company (including death, disability,
or retirement), a participant will receive the value of the participants vested interest in
his or her account in a lump-sum amount or in certain cases, the participant may have the
payment transferred to an IRA or another employer qualified plan, or prior to April 2002, the
participant may elect to purchase a commercially insured annuity contract for the life of the
participant. To
7
Watson Pharmaceuticals, Inc.
401(k) Plan
Notes to Financial Statements
December 31, 2007 and 2006
the extent an account is vested in the Company Stock Fund, payment of all or
part of that amount may be made in shares of Company common stock. Withdrawals are also
permitted for financial hardship, which is determined pursuant to the provisions of the IRC,
or, for a participants vested account balance after age 59 1/2. Effective January 1, 2006,
the Company also deleted two restrictions on service withdrawals; eliminating the
four-withdrawals-per year annual limit and the minimum $500 withdrawal requirement. Lastly,
the Company will allow hardship withdrawals for the following additional IRS events: funeral
or burial expenses relating to the death of participants spouse, child, parent, or other
eligible dependents as defined by the IRS and for payments relating to the repair of
participants principal residence due to certain catastrophic events.
Forfeitures
Forfeitures may be used to defray the reasonable costs and expenses of administering the
Plan. Any forfeiture in excess of those used to defray costs and expenses shall be used to
reduce Company matching contributions and profit sharing contributions, if any.
Approximately $188,000 and $80,000 of forfeited nonvested accounts were used to reduce
administrative expenses in 2007 and 2006, respectively. At December 31, 2007 and 2006,
forfeited nonvested accounts totaled approximately $55,000 and $62,000, respectively.
Administrative Expenses
To the extent permissible by applicable Department of Labor guidance, all expenses of
administering the Plan are paid by the Plan, unless paid by the Company. Professional fees
incurred in connection with the Plans annual compliance with ERISA and the Securities and
Exchange Commission Rules and Regulations are paid by the Company.
Plan Termination
Although it has not expressed any intent to do so, the Company has the right under the Plan
to discontinue its contributions at any time and to terminate the Plan, subject to the
provisions of ERISA. In the event of Plan termination, participants will become 100% vested
in their accounts and the net assets of the Plan will be allocated among the participants or
their beneficiaries, after payment of any expenses properly chargeable to the Plan, in
accordance with the provisions of ERISA.
2. Summary of Significant Accounting Policies
Basis of Accounting
The financial statements of the Plan have been prepared on an accrual basis and in conformity
with accounting principles generally accepted in the United States of America (GAAP).
Revenues are recorded as earned, benefits paid to participants are recorded when paid and all
other expenses are recorded as incurred.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities, and
disclosures of contingent assets and liabilities at the date of the financial statements and
the reported amounts of additions and deductions to net assets in the statement of changes in
net assets available for benefits during the reporting period. Actual results could differ
from those estimates.
8
Watson Pharmaceuticals, Inc.
401(k) Plan
Notes to Financial Statements
December 31, 2007 and 2006
Risks and Uncertainties
The Plan provides for various investment options in any combination of investment securities.
Investment securities are exposed to various risks including interest rate risk, market risk
and credit risk. Due to the level of risk associated with certain investment securities and
the level of uncertainty related to changes in the value of investment securities, it is at
least reasonably possible that changes in risks in the near term would materially affect
participants account balances and the amounts reported in the statements of net assets
available for benefits and the statement of changes in net assets available for benefits.
Investment Valuation and Income Recognition
The Plans investment contacts are carried at contract value, with adjustments from fair
value to contact value provided on the statement of net assets available for benefits. All
other investments are carried at fair value. If available, quoted market prices are used to
value investments. The Company stock fund is valued at its year-end unit closing price
(comprised of year-end market price plus uninvested cash position). Shares of registered
investment company mutual funds are valued at the net asset value of shares held by the Plan
at year end. Units held in common collective trusts are valued at the unit value as reported
by the investment manager using the audited financial statements of the trusts at year end.
Participant loans are valued at the unpaid principal amount of the loan, which approximates
fair value.
As described in Financial Accounting Standards Board (FASB) Staff Position (FSP) Nos. AAG
INV-1 and Statement of Position 94-4-1, Reporting of Fully Benefit-Responsive Investment
Contracts Held by Certain Investment Companies Subject to the AICPA Investment Company Guide
and Defined-Contribution Health and Welfare and Pension Plans (FSP AAG and SOP 94-4-1),
investment contracts held by a defined contribution plan are required to be reported at fair
value. However, contract value is the relevant measurement attribute for that portion of the
net assets available for benefits of a defined contribution plan attributable to fully
benefitresponsive investment contracts because contract value is the amount participants
would receive if they were to initiate permitted transactions under the terms of the plan.
FSP AAG and SOP 94-4-1 requires the statements of net assets available for benefits to
present the fair value of the investments, as well as the adjustment from fair value to
contract value for fully benefit-responsive investment contracts. As required by the FSP,
the statement of net assets available for benefits presents the fair value of the investment
contracts as well as the adjustment from fair value to contract value. The statement of changes in net assets
available for benefits is prepared on a contract value basis. We adopted FSP AAG and SOP
94-4-1 during 2006 and also applied this statement retroactively to the statement of net
assets available for benefits as of December 31, 2005.
Purchases and sales of securities are recorded on a trade-date basis. Interest income is
recorded on the accrual basis. Dividends are recorded on the ex-dividend date.
The net appreciation in fair value of investments consists of both the realized gains or
losses and unrealized appreciation and deprecation of those investments.
Payment of Benefits
Payments to participants are recorded when paid.
9
Watson Pharmaceuticals, Inc.
401(k) Plan
Notes to Financial Statements
December 31, 2007 and 2006
New Accounting Pronouncement
In September 2006, the FASB issued Statement of Financial Accounting Standards (SFAS) No.
157, Fair-Value Measurements (SFAS 157) which defines fair value, establishes a framework
for measuring fair value in GAAP and expands disclosures about fair-value measurements. SFAS
157 is effective for financial statements issued for fiscal years beginning after November
15, 2008. The adoption of SFAS 157 is not expected to have a material impact on the Plans
statement of net assets available for benefits or statement of changes in net assets
available for benefits.
3. Investments
The following presents investments that represent 5% or more of the Plans net assets at
December 31,:
|
|
|
|
|
|
|
|
|
|
|
2007 |
|
2006 |
Vanguard Retirement Savings Trust |
|
$ |
35,994,427 |
|
|
$ |
33,238,876 |
|
Vanguard 500 Index Fund |
|
|
24,817,517 |
|
|
|
23,279,426 |
|
T. Rowe Price Mid-Cap Growth Fund - Advisor Class |
|
|
20,485,542 |
|
|
|
18,323,145 |
|
American Funds Euro Pacific Growth Fund; R-4
Shares |
|
|
17,592,222 |
|
|
|
12,004,912 |
|
PIMCO Funds |
|
|
17,079,485 |
|
|
|
15,280,710 |
|
Vanguard Morgan Growth Fund |
|
|
12,143,475 |
|
|
|
10,469,380 |
|
For the years ended December 31, 2007 and 2006, the Plans investments (including realized
gains and losses on investments bought and sold and unrealized appreciation and depreciation
on investments held during the year) increased (decreased) in fair value as follows:
|
|
|
|
|
|
|
|
|
|
|
2007 |
|
|
2006 |
|
Mutual funds and common collective trusts |
|
$ |
2,292,971 |
|
|
$ |
7,529,030 |
|
Company common stock |
|
|
236,033 |
|
|
|
(1,045,612 |
) |
|
|
|
|
|
|
|
Net appreciation in fair value of investments |
|
$ |
2,529,004 |
|
|
$ |
6,483,418 |
|
|
|
|
|
|
|
|
Investment Contracts
The Vanguard Retirement Savings Trust (the Savings Trust) is designed to provide
preservation of capital and returns that are consistent regardless of stock and bond market
volatility. The Savings Trust seeks to earn a high level of income consistent with those
objectives. The Savings
Trust holds guaranteed investment contracts which typically have a fixed maturity. Each
contract contains a provision that the issuer will, if required, repay principal at the
stated contract value for the purpose of paying benefit payments (fully benefit-responsive).
In accordance with FSP AAG and SOP 94-4-1, the Trust is presented at fair value on the
statements of net assets available for benefits. The adjustment from fair value to contract
value is based on the contract value as reported
10
Watson Pharmaceuticals, Inc.
401(k) Plan
Notes to Financial Statements
December 31, 2007 and 2006
by Vanguard Fiduciary Trust Company (which
represents contributions made under the contracts, plus earnings, less withdrawals and
administrative expenses).
4. Related-Party Transactions
For the period January 1, 2006 through December 31, 2007, the plan assets include investments
in funds managed by The Vanguard Group, Inc., and Vanguard Fiduciary Trust Company. Vanguard
Fiduciary Trust Company acts as the Plans trustee and custodian and, therefore these
transactions qualify as party-in-interest transactions which are exempt from the prohibited
transaction rules under ERISA.
The Plan paid $65,000 to Vanguard Fiduciary Trust Company in fees and expenses for the years
ended December 31, 2007 and 2006, respectively. Broker commission fees for the Watson Stock
Fund transactions are paid by those participants who authorized the transactions. Expenses
for administering the Watson Stock Fund are paid directly by the Company.
The Plan held Company common stock with fair values of $4,840,000 and $4,694,000 at
December 31, 2007 and 2006, respectively. At December 31, 2007 and 2006, 178,335 and 180,322
shares of common stock of the Company are included in the Company Stock Fund, respectively.
The Plan made purchases and sales of the Company Stock Fund during 2007 and 2006.
5. Tax Status
The Internal Revenue Service has determined and informed the Company by letter dated June 24,
2002, that the Plan and related trust are designed in accordance with applicable sections of
the IRC. The Plan has been amended since receiving the determination letter, and the Company
believes the Plan continues to be operated in compliance with the applicable requirements of
the IRC. Accordingly, the Company believes that the Plan is qualified and the related trust
is tax exempt. Therefore, no provision for income taxes has been included in the Plans
financial statements.
6. Subsequent Events
Effective January 1, 2008, the Plan included a safe harbor feature. As described in the
following paragraphs, the Plan was amended to include expansion of the automatic enrollment
feature, a change in the Company matching contribution and an accelerated vesting schedule.
Automatic enrollment at 3% of eligible compensation was expanded for employees hired prior to
November 1, 2004 (the automatic enrollment feature effective date) who had not previously
contributed to the plan, eligible employees who were employed by Andrx Corporation (Andrx)
immediately before the merger between Watson and Andrx but who have not previously
contributed to the Plan and eligible employees hired on or after January 1, 2008. Deferral
rates for
these participants will automatically increase by 1% of eligible compensation annually
beginning on the first day of the pay period that begins on or immediately after the
anniversary of their Plan entry date up to 6%.
11
Watson Pharmaceuticals, Inc.
401(k) Plan
Notes to Financial Statements
December 31, 2007 and 2006
The Company match was changed to 100% on the first 2% and 50% on the next 4% of employee
deferrals.
The vesting schedule was amended whereby after one year of vesting service, participants will
be 50% vested in Watsons matching contributions. After two years of vesting service,
participants will be 100% vested in Watsons matching contributions.
7. Reconciliation to Form 5500
The following is a reconciliation of increase in net assets available for benefits per the
financial statements to the Form 5500 for the year ended December 31, 2007:
|
|
|
|
|
Total increase in net assets available for benefits per the financial statements |
|
$ |
27,180,770 |
|
Adjustment from fair value to contract value for fully
benefit-responsive investment contracts |
|
|
(316,798 |
) |
|
|
|
|
|
|
|
|
|
Total increase in net assets available for benefits per Form 5500 |
|
$ |
26,863,972 |
|
|
|
|
|
12
Watson Pharmaceuticals, Inc.
401(k) Plan
EIN: 95-3872914 PN:001
Schedule H, line 4i Schedule of Assets (Held at End of Year)
December 31, 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
Identity of issuer, |
|
|
|
|
|
|
|
|
|
borrower, lessor |
|
Description of investment including maturity date, rate of |
|
|
|
|
|
|
|
or similar party |
|
interest, collateral, par or maturity value |
|
Cost ** |
|
Current Value |
|
(a) |
|
(b) |
|
(c) |
|
(d) |
|
(e) |
|
Common stock: |
|
|
|
|
|
|
|
|
* |
|
Watson
Pharmaceuticals, Inc. |
|
Company Stock Fund |
|
|
|
$ |
4,840,014 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Mutual funds: |
|
|
|
|
|
|
|
|
|
|
Bond funds: |
|
|
|
|
|
|
|
|
|
|
PIMCO |
|
PIMCO Funds: Total Return Funds |
|
|
|
|
17,079,485 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock funds: |
|
|
|
|
|
|
|
|
|
|
American |
|
American Aadvantage Small Cap Value Fund PlanAhead
Class |
|
|
|
|
6,392,383 |
|
|
|
American |
|
American Funds Euro Pacific Growth Fund; R-4 Shares |
|
|
|
|
17,592,222 |
|
|
|
Artisan |
|
Artisan Mid Cap Value Fund: Investor Shares |
|
|
|
|
9,070,965 |
|
|
|
T. Rowe |
|
T. Rowe Price Mid-Cap Growth Fund, Inc: Advisor Class |
|
|
|
|
20,485,542 |
|
|
|
T. Rowe |
|
T. Rowe Small-Cap Growth Fund-Advisor Class |
|
|
|
|
7,489,163 |
|
* |
|
Vanguard |
|
Vanguard 500 Index Fund Investor Shares |
|
|
|
|
24,817,517 |
|
* |
|
Vanguard |
|
Vanguard Explorer Fund |
|
|
|
|
1,395,699 |
|
* |
|
Vanguard |
|
Vanguard Mid-Cap Index Fund |
|
|
|
|
8,261,325 |
|
* |
|
Vanguard |
|
Vanguard Morgan Growth Fund Investor Shares |
|
|
|
|
12,143,475 |
|
* |
|
Vanguard |
|
Vanguard Target Retirement 2005 Fund |
|
|
|
|
2,783,043 |
|
* |
|
Vanguard |
|
Vanguard Target Retirement 2010 Fund |
|
|
|
|
1,350,935 |
|
* |
|
Vanguard |
|
Vanguard Target Retirement 2015 Fund |
|
|
|
|
9,721,387 |
|
* |
|
Vanguard |
|
Vanguard Target Retirement 2020 Fund |
|
|
|
|
2,633,839 |
|
* |
|
Vanguard |
|
Vanguard Target Retirement 2025 Fund |
|
|
|
|
9,619,824 |
|
* |
|
Vanguard |
|
Vanguard Target Retirement 2030 Fund |
|
|
|
|
1,443,069 |
|
* |
|
Vanguard |
|
Vanguard Target Retirement 2035 Fund |
|
|
|
|
5,744,643 |
|
* |
|
Vanguard |
|
Vanguard Target Retirement 2040 Fund |
|
|
|
|
917,730 |
|
* |
|
Vanguard |
|
Vanguard Target Retirement 2045 Fund |
|
|
|
|
2,842,206 |
|
* |
|
Vanguard |
|
Vanguard Target Retirement 2050 Fund |
|
|
|
|
390,407 |
|
* |
|
Vanguard |
|
Vanguard Target Retirement Income |
|
|
|
|
862,687 |
|
* |
|
Vanguard |
|
Vanguard Windsor II Fund Investor Shares |
|
|
|
|
5,140,098 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
168,177,644 |
|
|
|
|
|
|
|
|
|
|
|
Common and collective trusts: |
|
|
|
|
|
|
|
|
* |
|
Vanguard |
|
Vanguard Retirement Savings Trust |
|
*** |
|
|
35,994,427 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other: |
|
|
|
|
|
|
|
|
* |
|
Participant Loans |
|
Varying maturity dates, interest ranging from 5% to
10.5% per annum |
|
|
|
|
5,790,771 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
214,802,856 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* |
|
Party-in-interest for which a statutory exemption exists. |
|
** |
|
Cost information may be omitted with respect to participant directed investments. |
|
*** |
|
At contract value which is less than fair value by $274,427. |
Under ERISA, an asset held for investment purposes is any amount held by the Plan on the last day
of the Plans fiscal year.
13
Watson Pharmaceuticals, Inc.
401(k) Plan
Signatures
The Plan
Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons
who administer the employee benefit plan) have duly caused this annual report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
By:
|
|
Watson Pharmaceuticals, Inc. 401(k) Plan
WATSON PHARMACEUTICALS, INC. as plan administrator |
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Susan Skara
Susan Skara
Chairman, Employee Benefit Plans Committee
|
|
|
Dated:
June 30, 2008
14
Index to Exhibits
|
|
|
Exhibit Number |
|
Description |
|
|
|
23.1
|
|
Consent of Independent Registered Public Accounting Firm |
15